• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[同时测定卵巢癌患者血浆及腹水中的Ca 125和D-二聚体]

[Simultaneous determination of Ca 125 and D-dimer in plasma and ascites in ovarian cancer].

作者信息

Schröck R, Hafter R, Graeff H, Schmid L

出版信息

Onkologie. 1985 Oct;8(5):260-2. doi: 10.1159/000215670.

DOI:10.1159/000215670
PMID:2999668
Abstract

In 37 patients with ovarian carcinoma stages Ic to IV the values of preoperatively determined tumour markers and the values of the follow-ups were examined in a trial to observe the course of the disease. The following sensitivity was recorded: Ca 125 92%, D-dimer 100%, TPA 76%, CEA 29%, CA 19-9 15%. Ca 125, D-dimer and TPA are unsuitable as follow-ups. They are also detectable in ascites.

摘要

在37例Ic至IV期卵巢癌患者中,对术前测定的肿瘤标志物值及随访值进行了检测,以观察疾病进程。记录到以下敏感度:癌抗原125(Ca 125)为92%,D - 二聚体为100%,组织多肽抗原(TPA)为76%,癌胚抗原(CEA)为29%,糖类抗原19 - 9(CA 19 - 9)为15%。Ca 125、D - 二聚体和TPA不适合用于随访。它们在腹水中也可检测到。

相似文献

1
[Simultaneous determination of Ca 125 and D-dimer in plasma and ascites in ovarian cancer].[同时测定卵巢癌患者血浆及腹水中的Ca 125和D-二聚体]
Onkologie. 1985 Oct;8(5):260-2. doi: 10.1159/000215670.
2
[Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Geburtshilfe Frauenheilkd. 1986 Jan;46(1):1-10. doi: 10.1055/s-2008-1036152.
3
[Comments on the paper by Schröck et al., The simultaneous determination of Ca 125 and D-dimer in plasma and ascitic fluid in ovarian cancer].
Onkologie. 1986 Feb;9(1):10.
4
[Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Gan No Rinsho. 1985 May;31(6 Suppl):655-63.
5
CA 125 and TPA as markers in ovarian carcinoma.癌抗原125和组织多肽抗原作为卵巢癌的标志物
Neth J Med. 1985;28(12):536-40.
6
[A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].[一项关于定位及血清数据的研究;卵巢癌中的四种肿瘤标志物(CA125、CA19-9、CEA和TPA)]
Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):47-54.
7
[New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Ann Ostet Ginecol Med Perinat. 1991 Jan-Feb;112(1):36-40.
8
Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
Gynecol Oncol. 1990 Oct;39(1):26-33. doi: 10.1016/0090-8258(90)90394-z.
9
[New developments in the area of markers in diagnosis and monitoring of ovarian cancer].[卵巢癌诊断与监测中标志物领域的新进展]
Onkologie. 1985 Oct;8(5):253-9. doi: 10.1159/000215669.
10
Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Gynecol Obstet Invest. 1987;23(3):200-7. doi: 10.1159/000298862.